Advertisement


William J. Gradishar, MD, on Hormone-Sensitive Breast Cancer: Treatment Update

NCCN 2018 Annual Conference

Advertisement

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses recent evidence on the efficacy, safety, and utility of HER2-targeted treatments in the adjuvant setting for early-stage and advanced breast cancers.



Related Videos

Breast Cancer

Anthony D. Elias, MD, on Triple-Negative Breast Cancer: Treatment Update

Anthony D. Elias, MD, of the University of Colorado Cancer Center, reviews promising experimental treatments, as well as PARP inhibitor therapy in TNBC, including the implications ...

Issues in Oncology

Lee N. Newcomer, MD, on Managed Care in America: Expert Perspective

Lee N. Newcomer, MD, who recently retired as Senior Vice President for Oncology and Genetics at UnitedHealth Group, discusses lessons learned during his long career in managed care...

Prostate Cancer

James L. Mohler, MD, on Prostate Cancer: Management Approaches

James L. Mohler, MD, of Roswell Park Cancer Institute, discusses personalized medicine, molecular risk stratification, and better androgen-deprivation therapy for men with prostate...

Leukemia

Ellin Berman, MD, on CML: Disease Management During Pregnancy

Ellin Berman, MD, of Memorial Sloan Kettering Cancer Center, discusses the effects of TKI therapy on fetal development, its impact on pregnancy outcomes, and how to develop an effe...

Skin Cancer

April K.S. Salama, MD, on Melanoma: Treating Recurrent or Progressive Distant Disease

April K.S. Salama, MD, of Duke Cancer Institute, talks about how to select systemic therapy for a patient with previously treated metastatic melanoma.

Advertisement

Advertisement



Advertisement